Acadia Pharma (ACAD) Tops Q2 EPS by 7c; Raises FY Rev Guidance
Tweet Send to a Friend
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
